# Acute Cholecystitis

Acute cholecystitis requires prompt distinction from alternative biliary and nonbiliary causes of right upper-quadrant pain, confirmation with imaging, assessment for sepsis or ductal complications, and timely source control. The supplied results do not contain disease-specific diagnostic or management guidance.

**Clinical question:** How should physicians diagnose, risk-stratify, and manage suspected acute cholecystitis?

Updated: 2026-08-20T23:35:00.688392Z

## What matters in practice
- The supplied search results contain no acute cholecystitis-specific guideline, diagnostic study, antimicrobial recommendation, procedural evidence, or dosing source; disease-specific management claims cannot be supported from this evidence set.
- Acute cholecystitis should be managed using current disease-specific surgical, gastroenterology, infectious diseases, and local antimicrobial guidance, which was not supplied.

## No usable disease-specific evidence was supplied

The retrieved sources do not address acute cholecystitis.

The supplied results concern colchicine, sitagliptin, finerenone, pulmonary embolism, peripheral artery disease, heart failure, diagnostic-test methodology, artificial intelligence, and guideline-development processes. None provides evidence specific to the diagnosis, severity grading, imaging sequence, antibiotics, timing of cholecystectomy, gallbladder drainage, choledocholithiasis evaluation, or post-procedural management of acute cholecystitis.

Because the requested article requires citations for diagnostic, pharmacologic, procedural, and prognostic claims and restricts use to supplied search results, a substantive point-of-care review would require unsupported assertions. No disease-specific recommendations, thresholds, doses, or algorithms are provided here.
- Do not use the included colchicine, sitagliptin, or finerenone prescribing information to guide treatment of acute cholecystitis; those sources address unrelated indications.[2][3][4]
- The diagnostic-test and machine-learning literature supplied is not evidence for evaluating or treating acute cholecystitis.[8][9][10][11]

*Relevance of supplied evidence to acute cholecystitis*

| Source group | Relevance | Permissible use for this topic |
| --- | --- | --- |
| Drug labeling for colchicine, sitagliptin, and finerenone | Unrelated indications and safety information.[2][3][4] | None for acute cholecystitis diagnosis or treatment. |
| Cardiovascular and pulmonary guidelines | Unrelated clinical conditions.[5][6][7][12] | None for acute cholecystitis. |
| Diagnostic and artificial-intelligence studies | General methodology or infection/sepsis test validation, not biliary disease management.[8][9][10][11] | None for disease-specific clinical recommendations. |

## Common questions

### What evidence is needed to create a point-of-care review of acute cholecystitis?

Relevant sources should include a current acute cholecystitis guideline, evidence for ultrasonography and second-line imaging, antimicrobial recommendations, trials or systematic reviews on early cholecystectomy and gallbladder drainage, and guidance for suspected common bile duct stones or cholangitis. None was supplied.

### Can this source set support antibiotic selection or procedural timing?

No. The available prescribing information concerns unrelated drugs, and no supplied source provides acute cholecystitis antibiotic regimens, renal adjustments, source-control indications, or timing evidence.[2][3][4]

## References
1. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f818ffe0-43df-4cc6-bc86-00b2c79b06fc&type=display
2. These highlights do not include all the information needed to use colchicine safely and effectively. See full prescribing information for Colchicine Tablets, USP. 
      Colchicine Tablets, USP, for oral use Initial U.S. Approval: 1961 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc439ae8-a79e-4942-8d02-22422b19b015&type=display
3. These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA.
      JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aaadccea-4842-493b-a0bd-0ee7645fc250
4. These highlights do not include all the information needed to use KERENDIA safely and effectively. See full prescribing information for KERENDIA. 
       KERENDIA (finerenone) tablets, for oral use  Initial U.S. Approval: 2021 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c&type=display
5. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001415
6. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001251
7. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
8. Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine — www.nature.com — https://www.nature.com/articles/s41591-025-03933-y
9. Development and validation of prognostic machine learning models for short- and long-term mortality among acutely admitted patients based on blood tests | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-56638-6
10. A unified framework for diagnostic test development and evaluation during outbreaks of emerging infections — www.nature.com — https://www.nature.com/articles/s43856-024-00691-9
11. The hidden risk of round numbers and sharp thresholds in clinical practice | npj Digital Medicine — www.nature.com — https://www.nature.com/articles/s41746-025-02079-y
12. ACC/AHA Guidelines for the Management of Patients With ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.cir.94.9.2341
13. A scoping review of evidence-based guidance and guidelines ... — academic.oup.com — https://academic.oup.com/fampra/article/41/4/404/7051177
14. Clinician Testing and Treatment Thresholds for Management ... — academic.oup.com — https://academic.oup.com/ofid/article/10/9/ofad455/7256803
15. Diagnostic testing and the evolution of detection avoidance by ... — academic.oup.com — https://academic.oup.com/emph/article/12/1/248/7742490
16. Impact of Individualized Versus Weight-Based Pain ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0099176724003799
17. Implementing ASH's guidelines for acute medical care ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2473952925001132
18. Acute Pain Management - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/acute-pain-management
19. Monitoring Procedure - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/monitoring-procedure
20. Clinical Practice Guidelines Development: Training and Resources — www.idsociety.org — https://www.idsociety.org/clinical-practice-guidelines-development-training-and-resources
21. Code and Guideline Changes | AMA — www.acc.org — https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Latest%20in%20Cardiology/Advocacy%20and%20Policy/2021-AMA-EM-clarificatons-030921
22. All Practice Guidelines: A-Z List — www.idsociety.org — https://www.idsociety.org/idsa_practice_guidelines
23. Policy Statements — www.annemergmed.com — https://www.annemergmed.com/article/S0196-0644(24)01070-9/fulltext
24. Practice Guidelines — www.aasld.org — https://www.aasld.org/practice-guidelines

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.